Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes

Endocrinology

Volumn 155, Issue 8, 2014, Pages 2797-2809

  Ben awadh, Abdullah N ^a   Delgado Calle, Jesus ^a,b   Tu, Xiaolin ^a   Kuhlenschmidt, Kali ^a   Allen, Matthew R ^a   Plotkin, Lilian I ^a,b   Bellido, Teresita ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BONE RESORPTION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MALE; MICE; MICE, TRANSGENIC; ORGAN CULTURE TECHNIQUES; OSTEOCYTES; PARATHYROID HORMONE; PRIMARY CELL CULTURE; RANK LIGAND; RECEPTORS, PARATHYROID HORMONE; SIGNAL TRANSDUCTION;

EID: 84905055066     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1046     Document Type: Article

References (35)

1. Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone. 2013; 54:250-257.
2. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146:4577-4583.
3. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005; 37:148-158.
4. Rhee Y, Bivi N, Farrow E, et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone. 2011; 49:636-643.
5. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010; 299:F882-F889.
6. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008; 3:e2942.
7. Rhee Y, Allen MR, Condon K, et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2011; 26:1035-1046.
8. Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30:3071-3085.
9. Xiong J, Onal M, Jilka RL, Weinstein R.S., Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17:1235-1241.
10. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17:1231-1234.
11. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res. 2002; 17:2068-2079.
12. Harris SE, MacDougall M, Horn D, et al. Meox2Cre-mediated disruption of CSF-1 leads to osteopetrosis and osteocyte defects. Bone. 2012; 50:42-53.
13. Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via adistant transcriptional enhancer. Mol Cell Biol. 2006; 26:6453-6468.
14. Kalajzic I, Braut A, Guo D, et al. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone. 2004; 35:74-82.
15. Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol. 1996; 132:195-210.
16. Stern AR, Stern MM, Van Dyke ME, Jähn K, Prideaux M., Bonewald LF. Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice. Biotechniques. 2012; 52:361-373.
17. Paic F, Igwe JC, Nori R, et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone. 2009; 45: 682-692.
18. Bivi N, Condon KW, Allen MR, et al. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res. 2012; 27:374-389.
19. Plotkin LI, Weinstein RS, Parfitt AM, Roberson P.K., Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bi-sphosphonates and calcitonin. J Clin Invest. 1999; 104:1363-1374.
20. Kato Y, Windle JJ, Koop BA, Mundy G.R., Bonewald LF. Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res. 1997; 12:2014-2023.
21. Islam S, Hassan F, Tumurkhuu G, et al. Receptor activator of nuclear factor-kappa B ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony-stimulating factor. Microbiol Immunol. 2008; 52:585-590.
22. O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 2013; 54:258-263.
23. Saini V, Marengi DA, Barry KJ, et al. Parathyroid hormone (PTH)/ PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem. 2013; 288:20122-20134.
24. Sakagami Y, Girasole G, Yu XP, Boswell H.S., Manolagas SC. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormoneintwo phenotypically distinct bone marrow-derived murine stromal cell lines. J Bone Miner Res. 1993; 8:811-816.
25. Feyen JH, Elford P, Di Padova FE, Trechsel U. Interleukin-6 is produced by bone and modulated by parathyroid hormone. J Bone Miner Res. 1989; 4:633-638.
26. Lin SC, Yamate T, Taguchi Y, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest. 1997; 100:1980-1990.
27. Romas E, Udagawa N, Zhou H, et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996; 183:2581-2591.
28. O'Brien CA. Control of RANKL gene expression. Bone. 2010; 46: 911-919.
29. Shin HI, Divieti P, Sims NA, et al. Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. Endocrinology. 2004; 145:1376-1385.
30. Allen MR, Burr DB. Bone modeling and remodeling. In: Burr D, Allen M, eds. Basic and Applied Bone Biology. 1st ed. Elsevier; 75-90; 2014.
31. Galli C, Zella LA, Fretz J.A., Fu Q., Pike JW, Weinstein RS, Manolagas SC, O'Brien CA. Targeted deletion of a distant transcriptional enhancer of the RANKL gene reduces bone remodeling and increases bone mass. Endocrinology. 2007; 149:146-153.
32. Onal M, Galli C, Fu Q, Xiong J., Weinstein RS, Manolagas SC, O'Brien CA. The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocri-nol. 2012; 26:341-348.
33. Rhee Y, Lee EY, Lezcano V, Ronda AC, Condon K.W., Allen MR, Plotkin LI, Bellido T. Resorption controls bone anabolism driven by PTH receptor signaling in osteocytes. J Biol Chem. 2013; 288: 29809-29820.
34. Bellido T, Plotkin LI, Bruzzaniti A. 2014 Bonecells. In: Burr D, Allen M, eds. Basic and Applied Bone Biology. First ed. Atlanta: Elsevier; 27-45.
35. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013; 382:50-56.